12/8
08:07 am
cing
Cingulate (NASDAQ:CING) had its price target lowered by analysts at Ascendiant Capital Markets from $62.00 to $58.00. They now have a "buy" rating on the stock.
Low
Report
Cingulate (NASDAQ:CING) had its price target lowered by analysts at Ascendiant Capital Markets from $62.00 to $58.00. They now have a "buy" rating on the stock.
11/19
01:29 pm
cing
Cingulate (NASDAQ:CING) had its price target lowered by analysts at Roth Capital from $17.00 to $16.00. They now have a "buy" rating on the stock.
Low
Report
Cingulate (NASDAQ:CING) had its price target lowered by analysts at Roth Capital from $17.00 to $16.00. They now have a "buy" rating on the stock.
11/17
05:35 pm
cing
CING: Third Quarter Results [Yahoo! Finance]
Low
Report
CING: Third Quarter Results [Yahoo! Finance]
11/13
08:38 am
cing
Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
High
Report
Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
11/13
08:00 am
cing
Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
High
Report
Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
11/10
08:40 am
cing
Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301 [Yahoo! Finance]
Low
Report
Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301 [Yahoo! Finance]
11/10
08:00 am
cing
Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301
Medium
Report
Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301
10/28
08:00 am
cing
Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control
Medium
Report
Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control
10/23
04:45 pm
cing
Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting
Medium
Report
Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting
10/15
02:24 pm
cing
Cingulate (NASDAQ:CING) had its price target raised by analysts at Roth Capital from $10.00 to $17.00. They now have a "buy" rating on the stock.
Medium
Report
Cingulate (NASDAQ:CING) had its price target raised by analysts at Roth Capital from $10.00 to $17.00. They now have a "buy" rating on the stock.
10/14
08:00 am
cing
FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date
Low
Report
FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date